

Reference:	FOI.5962.21
Subject:	Treatments for dermatological conditions
Date of Request:	7 May 2021

Requested:

1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
 - Adalimumab - Humira
 - Adalimumab Biosimilar
 - Apremilast
 - Brodalumab
 - Certolizumab
 - Dimethyl fumarate
 - Etanercept - Enbrel
 - Etanercept Biosimilar
 - Guselkumab
 - Infliximab - Remicade
 - Infliximab Biosimilar
 - Ixekizumab
 - Risankizumab
 - Secukinumab
 - Tildrakizumab
 - Ustekinumab

2. For the patients treated by the Dermatology department in the last three months with any of the above drugs, can you please provide the total number of paediatric (up to age 16) versus adult patients?

3. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
 - Adalimumab - Humira
 - Adalimumab Biosimilar
 - Golimumab
 - Infliximab - Remicade
 - Infliximab Biosimilar
 - Tofacitinib
 - Ustekinumab
 - Vedolizumab

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the medications prescribed and the number of patients treated in the Dermatology department, during the period February to April 2021.

Medication	Number
Amgevita-Adalimumab	47
Benepali-Etanercept	6
Cosentyx-Secukinumab	21
Humira-Adalimumab	*
Imraldi-Adalimumab	*
Otezla-Apremilast	23
Stelara-Ustekinumab	22

Please see the explanation below the response to question 3, in relation to the replacement of figures in the table with an asterisk.

- The UHB confirms that no paediatric patients were treated with the listed medications, during the period February to April 2021.
- The UHB provides, within the table overleaf, the medications prescribed and the number of patients treated in the Gastroenterology department, during the period February to April 2021.

Medication	Number
Amgevita-Adalimumab	78
Entyvio-vedolizumab INF	23
Entyvio-vedolizumab SC	18
Humira-Adalimumab	42
Inflectra-Infliximab	51
Remicade-Infliximab	*
Remsima SC - Infliximab	*
Simponi-Golimumab	*
Stelara-Ustekinumab	53
Xeljanz-Tofacitinib	*

Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018/General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.